Ronald Henzman, MD
Vascular & Interventional Radiology · Philadelphia, PANPI 1356735484
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $8,400 of the $13,556 with a category attached, or 62.0%. Penumbra, Inc. accounts for 77.8% of it on its own, with 13 other manufacturers making up the rest. 2025 is the largest year on record at $6,897, more than ten times the $521 reported in 2022.
Across 70 payments — averaging $193.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Penumbra, Inc.$11K
- Angiodynamics, Inc.$2K
- Baylis Medical Technologies Inc.$271
- Inari Medical, Inc.$243
- Shockwave Medical, Inc$154
- Boston Scientific$39
- plus $171 from 8 others
What the payments were for
- Speaking & faculty fees$8,40062%
- Travel & lodging$1,94914%
- Food & beverage$3,20724%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Penumbra, Inc. | 20 | $10,552 |
| Angiodynamics, Inc. | 26 | $2,126 |
| Baylis Medical Technologies Inc. | 2 | $271 |
| Inari Medical, Inc. | 3 | $243 |
| Shockwave Medical, Inc | 7 | $154 |
| Boston Scientific | 2 | $39 |
| Eagle Pharmaceuticals, Inc. | 2 | $32 |
| Gilead | 2 | $27 |
| Siemens Medical Solutions USA, Inc. | 1 | $23 |
| Abbott | 1 | $21 |
| Phathom Pharmaceuticals, Inc. | 1 | $19 |
| Teleflex LLC | 1 | $18 |
| AbbVie | 1 | $17 |
| Merck | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,556 in reported general payments places this provider in the 85th percentile of 223 vascular & interventional radiology providers in Pennsylvania.
See all vascular & interventional radiology providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 26 | $27,418 |
Paid to pharmacies, not to this prescriber.
Other vascular & interventional radiology in Philadelphia
- Timothy ClarkPhiladelphia$813K
- Scott TrerotolaPhiladelphia$761K
- Abhishek KumarPhiladelphia$410K
- Jason HoffmannPhiladelphia$241K
- Michael SoulenPhiladelphia$155K
- Noor AhmadPhiladelphia$111K
- Stephen HuntPhiladelphia$79K
- Kenneth ChoPhiladelphia$72K
- Carin GonsalvesPhiladelphia$55K
- Susan Shamimi-NooriPhiladelphia$43K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.